Vaccine Adjuvants Market Growth, Market Insights and Forecast to 2025

Posted by rekha on November 28th, 2019

 “The Global Vaccine Adjuvants Market was valued at US$ 533.1 Mn in 2018 and is expected to grow at a significant CAGR over six years forecast period 2019-2025 owing to rising elderly population coupled with rising usage of adjuvants in vaccines”

Precision Business Insights (PBI) in its report titled “Global Vaccine Adjuvants Market: Market Estimation, Dynamics, Regional Share, Trends, Competitor Analysis 2018 and Forecast 2019-2025” assesses the market performance over six years forecast period over 2019-2025. The report analyses the market value forecast and provides the strategic insights into the market driving factors, challenges that are hindering the market revenue growth over forecast period.

The global vaccine adjuvants market was valued at US$ 533.1 Mn in 2018 and growing at a CAGR of 5.3% over the forecast period owing to surge in the occurrence of several zoonotic and other communicable diseases, rising adoption for developed vaccination against innumerable diseases, Increasing efforts from the government to focus on organizing the vaccination programs, usage of synthetic and recombinant vaccines is increasing which is anticipated to boost the growth of the market over the forecast period. Additionally, upsurge in the incidence of livestock & companion animal diseases, advancements in technology for the development of vaccine adjuvants, and government funding for research and development activities are projected to drive the growth of the market. However, strict regulatory guidelines, high cost for the R&D activities, and side effects associated with the vaccine adjuvants are anticipated to hinder the growth of the market.

Global vaccine adjuvants market segmented on the product type, vaccine type, route of administration, application, end user, and region.

Request for Sample Report @ https://www.precisionbusinessinsights.com/request-sample?product_id=17173

Particulate adjuvants segment accounted for higher revenue share

Based on product type, global vaccine adjuvants market is segmented pathogen components, combination adjuvants, particulate adjuvants, adjuvant emulsions, and others. Particulate adjuvants segment accounted for the largest market share in 2018 and is expected to grow with highest CAGR over the forecast period owing to increasing occurrence of diseases such as cancer, allergy, and HIV/AIDS, rising demand for innovative treatment options, and advancement of better-quality vaccine immunization.

North America holds leading position in Global Vaccine Adjuvants Market

PBI’s global vaccine adjuvants market report analyses the market in different regions such as North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. According to regional analysis, North America is expected to account for larger revenue share in 2018 and the same trend is projected to follow over 2019-2025 owing to increasing prevalence of infective diseases, initiatives by the government on infectious diseases, strategic collaborations with the research institutes for R&D activities on vaccine adjuvants are anticipated to boost the growth of the market. For instance, in July 2016, U.S. Army Medical Research Institute of Infectious Diseases has collaborated with China’s Jilin Jian Yisheng Biopharma for the development of Ebola PIKA adjuvant vaccine. Europe holds a noteworthy share in vaccine adjuvants market due to increasing prevalence of influenza, cancer, and other communicable diseases, rising awareness regarding the vaccine adjuvant applications in the development of vaccines, and growing R&D activities are projected to boost the market growth. Asia Pacific vaccine adjuvants market is expected to grow with significant CAGR over the forecast years.

Recent Developments in the Global Vaccine Adjuvants Market

• In January 2019, Croda International Plc., announced that it has acquired Brenntag Biosector
• In January 2016, Phibro Animal Health Corporation has acquired business of MVP Laboratories, Inc., and animal vaccine and adjuvant manufacturer
• In November 2016, The Scripps Research Institute has collaborated with Yisheng Biopharma for testing the Yisheng’s PIKA vaccine adjuvants against HIV infection.

Key player’s profiles in the report are Invivogen (U.S.), MVP Laboratories, Inc. (U.S.), CSL Limited (Australia), SEPPIC (France), Brenntag Biosector (Denmark), Novavax, Inc. (U.S.), Agenus, Inc. (U.S.), OZ Biosciences (France), and Jilin Jian Yisheng Biopharma Co. Ltd. (China) to name a few.

Detailed Segmentation

By Product Type

o   Pathogen components

o   Combination adjuvants

o   Particulate adjuvants

o   Adjuvant emulsions

o   Others

By Vaccine Type   

o   Human vaccines

o   Veterinary vaccines

By Route of Administration  

o   Oral

o   Mucosal

o   Parenteral

o   Others

By Application 

o   Infectious diseases

o   Cancer

o   Others

By End User 

o   Pharmaceutical industries

o   Biotechnology industries

o   Veterinary vaccine manufacturing industries

Geography

o     North America

• U.S
• Canada

o     Europe

• Germany
• France
• U.K
• Italy
• Spain
• Russia
• Poland
• Rest of Europe

o     Asia-Pacific

• Japan
• China
• India
• Australia & New Zealand
• ASEAN (Includes Indonesia, Thailand, Vietnam, Philippines, Malaysia, and Others)
• South Korea
• Rest of Asia-Pacific

o     Latin America

• Brazil
• Mexico
• Argentina
• Venezuela
• Rest of Latin America

o     Middle East and Africa (MEA)

• Gulf Cooperation Council (GCC) Countries
• Israel
• South Africa
• Rest of MEA

For more information: https://www.precisionbusinessinsights.com/market-reports/global-vaccine-adjuvants-market/